Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Gingrich, Diane E; Lisko, Joseph G; Curry, Matthew A; Cheng, Mangeng; Quail, Matthew; Lu, Lihui; Wan, Weihua; Albom, Mark S; Angeles, Thelma S; Aimone, Lisa D; Haltiwanger, R Curtis; Wells-Knecht, Kevin; Ott, Gregory R; Ghose, Arup K; Ator, Mark A; Ruggeri, Bruce; Dorsey, Bruce D.
J Med Chem; 55(10): 4580-93, 2012 May 24.
Artigo em Inglês | MEDLINE | ID: mdl-22564207
Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib. Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties. Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, 25b. A striking feature of 25b over previously described ALK inhibitors is its >600-fold selectivity over insulin receptor (IR), a closely related kinase family member. Most importantly, 25b exhibited dose proportional escalation in rat compared to compound 3 which suffered dose limiting absorption preventing further advancement. Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclinical models.
Selo DaSilva